Your browser doesn't support javascript.
loading
Do Histologically Aggressive Subtypes of Papillary Thyroid Microcarcinoma have Worse Clinical Outcome than Non-Aggressive Papillary Thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study.
Zuhur, Sayid Shafi; Aggul, Hunkar; Avci, Ugur; Erol, Selvinaz; Tuna, Mazhar Müslüm; Uysal, Serhat; Akbaba, Gulhan; Kilinç, Faruk; Catak, Merve; Tekin, Sakin; Bilen, Ogun Irem; Öztürk, Beyza Olcay; Erden, Ecem Bilgehan; Elbuken, Gulsah; Yavuz, Halise Cinar; Kadioglu, Pinar; Cinar, Nese; Kutluturk, Faruk; Bayraktaroglu, Taner; Topçu, Birol; Arslan, Aysegul Isal; Gucer, Hasan; Cihangiroglu, Gulcin; Topal, Cumhur Selcuk; Ozturk, Tulin; Tekin, Leyla; Artas, Gokhan; Akcay, Elif; Gun, Banu Dogan; Altuntas, Yuksel.
Afiliación
  • Zuhur SS; Department of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Aggul H; Department of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Avci U; Department of Endocrinology and Metabolism, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
  • Erol S; Department of Endocrinology and Metabolism, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
  • Tuna MM; Department of Endocrinology and Metabolism, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Uysal S; Department of Endocrinology and Metabolism, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Akbaba G; Department of Endocrinology and Metabolism, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
  • Kilinç F; Department of Endocrinology and Metabolism, Faculty of Medicine, Elazig Firat University, Elazig, Turkey.
  • Catak M; Department of Endocrinology and Metabolism, Faculty of Medicine, Tokat Gaziosmanpasa University, Tokat, Turkey.
  • Tekin S; Department of Endocrinology and Metabolism, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
  • Bilen OI; Department of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Öztürk BO; Department of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Erden EB; Department of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Elbuken G; Department of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Yavuz HC; Department of Endocrinology and Metabolism, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Kadioglu P; Department of Endocrinology and Metabolism, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Cinar N; Department of Endocrinology and Metabolism, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
  • Kutluturk F; Department of Endocrinology and Metabolism, Faculty of Medicine, Elazig Firat University, Elazig, Turkey.
  • Bayraktaroglu T; Department of Endocrinology and Metabolism, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
  • Topçu B; Department of Biostatistics, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Arslan AI; Department of Pathology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Gucer H; Department of Pathology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
  • Cihangiroglu G; Department of Pathology, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
  • Topal CS; Department of Pathology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
  • Ozturk T; Department of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Tekin L; Department of Pathology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
  • Artas G; Department of Pathology, Faculty of Medicine, Elazig Firat University, Elazig, Turkey.
  • Akcay E; Department of Pathology, Faculty of Medicine, Tokat Gaziosmanpasa University, Tokat, Turkey.
  • Gun BD; Department of Pathology, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
  • Altuntas Y; Department of Endocrinology and Metabolism, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
Horm Metab Res ; 55(5): 323-332, 2023 May.
Article en En | MEDLINE | ID: mdl-36764327
ABSTRACT
Histologically aggressive micropapillary thyroid carcinomas (PTMC) subtypes are thought to be associated with an aggressive clinical course. However, evidence for unfavorable clinical outcomes in patients with aggressive PTMC subtypes is not clear. In this study, we intended to determine the difference in clinical outcomes between patients with aggressive and non-aggressive PTMC subtypes. In this multicenter cohort study, the computer-recorded clinical and histopathological data of patients who underwent thyroid surgery between January 2000 - January 2021 in 9 referral centers and were diagnosed as PTMC were analyzed. A total of 1585 patients [female 1340 (84.5%), male 245 (15.5%), mean age 47.9±11.63 years), with a mean follow-up time of 66.55±37.16 months], were included in the study. Ninety-eight cases were diagnosed as aggressive and 1487 as non-aggressive subtypes. Persistent/recurrent disease was observed in 33 (33.7% )and 41 (2.8%) patients with aggressive and non-aggressive subtypes (p<0.001). Diseases-free survival rates were markedly lower in patients with aggressive than in those with non-aggressive PTMC subtypes (66.3 vs. 94.8%, log-rank p<0.001). Moreover, in multivariate analysis, aggressive histology was an independent predictor of persistent/recurrent disease, after controlling for other contributing factors (HR 5.78, 95% CI 3.32-10, p<0.001). Patients with aggressive PTMC subtypes had higher rates of incomplete biochemical and structural response than patients with non-aggressive subtypes as well (p<0.001). Aggressive PTMC subtypes share many characteristics with histologically identical tumors>1 cm in size. Therefore, the histopathological subtype of PTMC should be taken into consideration to tailor a personalized management plan.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Carcinoma Papilar Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Carcinoma Papilar Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article